The scope of drug discovery research has grown immensely in recent decades. Previously uncharted areas of discovery continue to emerge sparking inspiration and focus for scientists, organizations and even countries as a whole. One such research area that has gained momentum over the last 10 years is nonalcoholic steatohepatitis (NASH). NASH describes inflammation and damage of the liver caused by a buildup of fat. NASH is estimated to impact as much as 12% of the US population and is expected to become the leading cause of liver transplantation by 2020.